STK17A Antikörper (N-Term)

Produktnummer ABIN6990303

Dieses Anti-STK17A-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von STK17A in WB, ELISA, ICC und IF. Geeignet für Human.

Kurzübersicht für STK17A Antikörper (N-Term) (ABIN6990303)

Target: STK17A (serine/threonine Kinase 17a (STK17A))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser STK17A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Immunofluorescence (IF)

Produktdetails anti-STK17A Antikörper

Bindungsspezifität: N-Term

Spezifität: No cross responses to DRAK2, DAP or ZIP kinases.

Aufreinigung: DRAK1 Antibody is affinity chromatography purified via peptide column.

Immunogen: DRAK1 antibody was raised against a peptide corresponding to amino acids near the amino terminus of human DRAK1. The immunogen is located within the first 50 amino acids of DRAK1.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: DRAK1 antibody can be used for detection of DRAK1 by Western blot at 1 μ,g/mL. An approximately 50 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 2 μ,g/mL. For immunofluorescence start at 10 μ,g/mL.

Antibody validated: Western Blot in human samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: DRAK1 Antibody is supplied in PBS containing 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,4 °C

Informationen zur Lagerung: DRAK1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Details zu STK17A

Target: STK17A (serine/threonine Kinase 17a (STK17A))

Andere Bezeichnung: DRAK1

Hintergrund: DRAK1 Antibody: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 for DAP kinase-related apoptosis-inducing protein kinases. DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK1 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK1 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

Molekulargewicht: 50 kDa

Gen-ID: 9263

UniProt: Q9UEE5